Palisade Bio
PALI
4 hedge funds and large institutions have $10.4M invested in Palisade Bio in 2016 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
42% more call options, than puts
Call options by funds: $88K | Put options by funds: $62K
0% more funds holding
Funds holding: 4 → 4 (0)
0% more ownership
Funds ownership: 0% → 0% (0%)
31% less capital invested
Capital invested by funds: $15.1M → $10.4M (-$4.7M)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SBIA
Sheaff Brock Investment Advisors
Indianapolis,
Indiana
|
-$85K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$31K |
PALI Hedge Fund Activity: Q1 2016 in Review
4 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q1 2016, worth a combined $10.4M — down 31% from $15.1M a quarter earlier.
Fund positioning in PALI was balanced in Q1 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Sheaff Brock Investment Advisors, cutting an estimated $85K.
- 4 institutional investors held Palisade Bio (PALI) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $10.4M of Palisade Bio stock for Q1 2016, down 31% quarter-over-quarter.
- 0 funds opened new Palisade Bio positions in Q1 2016 and 0 closed out.
- The largest Palisade Bio seller in Q1 2016 was Sheaff Brock Investment Advisors, an estimated $85K sold.
Based on aggregated 13F filings for Q1 2016.